CG
Christopher Gibson (Director) filed 13 Form 4 reports in the trailing twelve months (0 purchases, 13 sales), most often in Recursion Pharmaceuticals, Inc. (RXRX). The largest single filing was $185K of RXRX (40,000 sh × $4.63, as filed), executed Dec 4 2025. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
13
0 buys · 13 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$1.8M
shares × price, as filed
Last traded
Jun 5
Filed Jun 5
Median ADV $67.5M across their filed names
Open performance→Volume by month
Buys $0
Sells $10.0M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
13 filings
Sector per market data · by filing · past 12 months
Most traded names
RXRXRecent filings
RXRXSALE
Recursion Pharmaceuticals, Inc.
View filing →
$476K100,000 sh × $4.76
Exec Sep 25 2025
Filed Sep 26 2025 · 5:30 PM ET RXRXSALE Recursion Pharmaceuticals, Inc. View filing → $471K
100,000 sh × $4.71
Exec Sep 10 2025
Filed Sep 12 2025 · 5:30 PM ET RXRXSALE Recursion Pharmaceuticals, Inc. View filing → $484K
100,000 sh × $4.84
Exec Aug 26 2025
Filed Aug 28 2025 · 5:30 PM ET RXRXSALE Recursion Pharmaceuticals, Inc. View filing → $3.2M
600,300 sh across 2 lots
Exec Aug 11 2025
Filed Aug 13 2025 · 5:30 PM ET RXRXSALE Recursion Pharmaceuticals, Inc. View filing → $837K
138,574 sh × $6.04
Exec Mar 27 2025
Filed Mar 28 2025 · 5:30 PM ET RXRXSALE Recursion Pharmaceuticals, Inc. View filing → $259K
40,000 sh across 2 lots
Exec Mar 5 2025
Filed Mar 7 2025 · 5:30 PM ET RXRXSALE Recursion Pharmaceuticals, Inc. View filing → $316K
40,000 sh across 2 lots
Exec Feb 5 2025
Filed Feb 7 2025 · 5:30 PM ET RXRXSALE Recursion Pharmaceuticals, Inc. View filing → $287K
40,000 sh across 2 lots
Exec Jan 8 2025
Filed Jan 13 2025 · 5:30 PM ET † More filings →